An October 31 headline raised a question about first-patient dosing in Incyte’s colorectal cancer pipeline. But the supplied information doesn’t identify the trial or explain the dosing.
The available facts include no trial name, treatment details, patient count, or company statement. So they don’t establish what happened or why it matters. Incyte’s shares last closed at US$118.01, and reported volume was well below the 20-day average.
Investor takeaway: The headline points to a possible clinical trial milestone, but there isn’t enough information here to confirm the details or assess its significance.
Incyte Corporation
INCY.US
INCY.US
Incyte Corporation
WealthAwesomeMarket cap
$25.04B
P/E
62.7x
52W high
$132.60
52W low
$89.25
1W change
+5.12%
Beta
0.78
Analyst Price Targets
Based on 28 analysts covering INCY · as of Nov 6, 2026
Wall Street analysts forecast INCY stock price to rise 10.9% over the next 12 months.
Consensus
Buy3.75 / 5.00
Avg. Target
C$130.92
+10.9% Upside
Previously C$131.08 on Nov 4, 2026
Current Price
C$118.01
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on INCY's historical volatility
30-Day Vol
33.3%
Annualized
90-Day Vol
31.9%
Annualized
Trend (90d)
-9.7%
Annualized drift
90d Mean
C$113.99
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$116.65 | C$104.00 – C$130.84 |
| 60 trading days | C$115.31 | C$98.03 – C$135.64 |
| 90 trading days | C$113.99 | C$93.43 – C$139.06 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
US$118.01 last close; latest volume at 0.84× its 20-day average
Incyte’s last close was US$118.01. Latest volume was 2,171 shares, compared with a 20-day average of 1,895,507. These figures don’t show that the dosing headline affected the share price.
Bull case
The headline points to a possible pipeline milestone. Incyte shares are up 21.13% year to date, according to the supplied figures.
Bear case
The supplied information includes no trial details, clinical results, or company announcement. Latest reported volume was 0.84 times the 20-day average.
What happened: a dosing headline, with few details
An October 31 headline asks what first-patient dosing means for Incyte’s colorectal cancer pipeline. The supplied facts don’t name the study, drug, trial phase, participating sites, or number of patients dosed. They also include no clinical results or direct company announcement about the milestone.
Without those details, the headline doesn’t show what the treatment is intended to do or where the trial stands. You can follow INCY.US on the Incyte stock page, but the trial information isn’t provided here.
What the numbers show: shares up, reported volume well below average
Incyte’s last close was US$118.01. The supplied figures show gains of 4.47% over one day, 5.12% over one week, 7.64% over one month, and 21.13% year to date. Latest volume was 2,171 shares, or 0.84 times the 20-day average of 1,895,507 shares.
These figures describe the stock, but they don’t establish that the October 31 headline drove a price move. The supplied information doesn’t include a dated share-price reaction to the dosing news. The close was US$120.12 against the 50-day moving average and US$108.19 against the 200-day average. Other supplied figures include a P/E of 62.6786 and a market capitalization of US$25,040,822,272.
What to watch next: confirmation and trial details
The main unanswered questions are which study is involved, what treatment it’s testing, and what first-patient dosing means for the trial. Those details would help show whether this is an early development step and what milestones may follow. They aren’t included in the supplied information.
The October 31 headline is the only item provided about colorectal cancer dosing. Later headlines concern a hematology conference presentation and investor conferences, not this trial. Incyte’s INCY listing and available stock information offer market context, but don’t confirm the clinical details.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
